Skip to main content
. 2023 Jun 8;7(9):1097–1112. doi: 10.1038/s41551-023-01050-0

Extended Data Fig. 5. In vivo pharmacokinetics, biodistribution and safety profile.

Extended Data Fig. 5

(a) Organ autoradiography 24 h after 89Zr-IL4-aNPs injection in mice. (b) Gamma count in vital organs 24 h after 89Zr-IL4-aNPs injection in mice (n = 5). (c) Uptake ratios by target organs over clearance organs in mice 2-way ANOVA with Turkey post-hoc analysis. (d) Dynamic PET/MRI scans of non-human primates at 1, 30, and 60 minutes after 89Zr-IL4-aNPs injection. (e) Organ-specific SUVmean in non-human primates over 1 hour following 89Zr-IL4-aNPs administration. (f) Gating strategy for bone marrow (top) and spleen (bottom) in experiments to measure cell type-specificity of DiO-labelled discoidal IL4-aNPs. Data are presented as mean ± SD where appropriate.